168 related articles for article (PubMed ID: 31534196)
1. Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation.
Nykolyszyn C; Granata A; Pagliardini T; Castagna L; Harbi S; Bouabdallah R; Vey N; Fürst S; Maisano V; Legrand F; Lemarié C; Calmels B; Chabannon C; Weiller PJ; Blaise D; Devillier R
Bone Marrow Transplant; 2020 Feb; 55(2):349-355. PubMed ID: 31534196
[TBL] [Abstract][Full Text] [Related]
2. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
3. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies.
Duléry R; Brissot E; Mohty M
Blood Rev; 2023 Nov; 62():101080. PubMed ID: 37085459
[TBL] [Abstract][Full Text] [Related]
4. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
[TBL] [Abstract][Full Text] [Related]
5. The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation.
Dybko J; Sobczyk-Kruszelnicka M; Makuch S; Agrawal S; Dudek K; Giebel S; Gil L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982839
[TBL] [Abstract][Full Text] [Related]
6. Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation.
El-Cheikh J; Devillier R; Dulery R; Massoud R; Al Chami F; Ghaoui N; Moukalled N; Pagliardini T; Marino F; Malard F; Bazarbachi AH; Mohty R; Bazarbachi A; Castagna L; Mohty M; Blaise D
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):617-623. PubMed ID: 32457025
[TBL] [Abstract][Full Text] [Related]
7. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors.
Montoro J; Piñana JL; Hernández-Boluda JC; Hernani R; Lorenzo I; Pérez A; Guerreiro M; Balaguer-Rosello A; Sanz GF; Carretero C; Albert E; Navarro D; Sanz MA; Solano C; Sanz J
Bone Marrow Transplant; 2020 Nov; 55(11):2147-2159. PubMed ID: 32371901
[TBL] [Abstract][Full Text] [Related]
8. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
9. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
Battipaglia G; Labopin M; Kröger N; Vitek A; Afanasyev B; Hilgendorf I; Schetelig J; Ganser A; Blaise D; Itälä-Remes M; Passweg JR; Bonifazi F; Finke J; Ruggeri A; Nagler A; Mohty M
Blood; 2019 Sep; 134(11):892-899. PubMed ID: 31270102
[TBL] [Abstract][Full Text] [Related]
10. Influence of HLA 1-3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation.
Kawamura K; Kanda J; Ohashi K; Fukuda T; Iwato K; Eto T; Fujiwara SI; Mori T; Fukushima K; Ozawa Y; Uchida N; Ashida T; Ichinohe T; Atsuta Y; Kanda Y
Ann Hematol; 2020 May; 99(5):1099-1110. PubMed ID: 32206853
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.
Bailén R; Kwon M; Pascual-Cascón MJ; Ferrà C; Sanz J; Gallardo-Morillo A; García-Sola A; Torrent A; Jiménez-Lorenzo MJ; Piñana JL; Montoro J; Oarbeascoa G; Dorado N; Gómez-Centurión I; Muñoz C; Martínez-Laperche C; Anguita J; Buño I; Díez-Martín JL;
Ann Hematol; 2021 Feb; 100(2):541-553. PubMed ID: 33140137
[TBL] [Abstract][Full Text] [Related]
14. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
[TBL] [Abstract][Full Text] [Related]
15. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.
Wakamatsu M; Terakura S; Ohashi K; Fukuda T; Ozawa Y; Kanamori H; Sawa M; Uchida N; Ota S; Matsushita A; Kanda Y; Nakamae H; Ichinohe T; Kato K; Murata M; Atsuta Y; Teshima T;
Blood Adv; 2019 Jan; 3(2):105-115. PubMed ID: 30626574
[TBL] [Abstract][Full Text] [Related]
16. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
Kanate AS; Mussetti A; Kharfan-Dabaja MA; Ahn KW; DiGilio A; Beitinjaneh A; Chhabra S; Fenske TS; Freytes C; Gale RP; Ganguly S; Hertzberg M; Klyuchnikov E; Lazarus HM; Olsson R; Perales MA; Rezvani A; Riches M; Saad A; Slavin S; Smith SM; Sureda A; Yared J; Ciurea S; Armand P; Salit R; Bolaños-Meade J; Hamadani M
Blood; 2016 Feb; 127(7):938-47. PubMed ID: 26670632
[TBL] [Abstract][Full Text] [Related]
18. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation.
Devillier R; Labopin M; Chevallier P; Ledoux MP; Socié G; Huynh A; Bourhis JH; Cahn JY; Roth-Guepin G; Mufti G; Desmier D; Michallet M; Fegueux N; Ciceri F; Baron F; Blaise D; Nagler A; Mohty M
Bone Marrow Transplant; 2018 Apr; 53(4):431-437. PubMed ID: 29330391
[TBL] [Abstract][Full Text] [Related]
19. Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies.
Chen TT; Lin CC; Lo WJ; Hsieh CY; Lien MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP
Int J Hematol; 2022 Apr; 115(4):525-533. PubMed ID: 35226308
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
